Should I buy or sell Amgen stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares. View AMGN analyst ratings or view top-rated stocks .

What is Amgen's stock price target for 2024?

19 Wall Street analysts have issued 1 year price objectives for Amgen's shares. Their AMGN share price targets range from $200.00 to $350.00. On average, they expect the company's share price to reach $295.30 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price. View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts .

How have AMGN shares performed in 2024?

Amgen's stock was trading at $288.02 at the start of the year. Since then, AMGN stock has increased by 1.1% and is now trading at $291.12. View the best growth stocks for 2024 here .

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our AMGN earnings forecast .

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, February, 6th. The medical research company reported $4.71 EPS for the quarter, beating the consensus estimate of $4.66 by $0.05. The medical research company had revenue of $8.20 billion for the quarter, compared to analysts' expectations of $8.13 billion. Amgen had a net margin of 23.83% and a trailing twelve-month return on equity of 154.27%. Amgen's revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm posted $4.09 earnings per share. Read the conference call transcript .

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Tuesday, December 12th. Stockholders of record on Friday, February 16th will be given a dividend of $2.25 per share on Thursday, March 7th. This represents a $9.00 annualized dividend and a dividend yield of 3.09%. The ex-dividend date is Thursday, February 15th. This is an increase from the stock's previous quarterly dividend of $2.13. Read our dividend analysis for AMGN .

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $9.00 per share and currently has a dividend yield of 2.93%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 72.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.82% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for AMGN .

What ETFs hold Amgen's stock?

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN) , VanEck Biotech ETF (BBH) , Invesco Nasdaq Biotechnology ETF (IBBQ) , iShares Biotechnology ETF (IBB) , ProShares Ultra Nasdaq Biotechnology (BIB) , Invesco Pharmaceuticals ETF (PJP) , FT Vest DJIA Dogs 10 Target Income ETF (DOGG) and Invesco Dow Jones Industrial Average Dividend ETF (DJD) .

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of 18.900-20.300 for the period, compared to the consensus estimate of 20.000. The company issued revenue guidance of $32.4 billion-$33.8 billion, compared to the consensus revenue estimate of $32.7 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com . Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ) , NVIDIA (NVDA) , Intel (INTC) , Cisco Systems (CSCO) , Pfizer (PFE) , AbbVie (ABBV) , Walt Disney (DIS) , AT&T (T) , Alibaba Group (BABA) and Home Depot (HD) .

Who are Amgen's major shareholders?

Amgen's stock is owned by many different retail and institutional investors. Top institutional investors include Primecap Management Co. CA (2.73%), Charles Schwab Investment Management Inc. (1.94%), Norges Bank (1.01%), California Public Employees Retirement System (0.51%), Dimensional Fund Advisors LP (0.46%) and LSV Asset Management (0.34%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon , Nancy A Grygiel , Nancy A Grygiel , R Sanders Williams , Robert Eckert , Ronald D Sugar and Ronald D Sugar . View institutional ownership trends .

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Amgen have any subsidiaries?

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc.. Read More

NASDAQ:AMGN

Amgen (AMGN) Stock Price, News & Analysis

$291.12

-3.73 (-1.27%)

(As of 02/9/2024 08:55 PM ET)

Compare

Today's Range: $289.71
▼
$295.00
50-Day Range: $269.12
▼
$324.56
52-Week Range: $211.71
▼
$329.72

Volume: 3.34 million shs
Average Volume: 3.03 million shs
Market Capitalization: $155.80 billion

P/E Ratio: 23.31
Dividend Yield: 3.09%
Price Target: $295.30

Get Amgen alerts:

Amgen MarketRank™ Stock Analysis

Analyst Rating: Hold
2.47 Rating Score
Upside/Downside: 1.4% Upside
$295.30 Price Target
Short Interest: Healthy
1.66% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.42
Upright™ Environmental Score
News Sentiment: 0.27
Based on 86 Articles This Week
Insider Trading: Selling Shares
$572,271 Sold Last Quarter
Proj. Earnings Growth: 7.57%
From $19.54 to $21.02 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.89 out of 5 stars

Medical Sector

22nd out of 922 stocks

Drug Manufacturers - General Industry

1st out of 1 stocks

2.2

Analyst's Opinion

Consensus Rating
Amgen has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 10 buy ratings, 8 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $295.30, Amgen has a forecasted upside of 1.4% from its current price of $291.12.
Amount of Analyst Coverage
Amgen has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
1.66% of the float of Amgen has been sold short.
Short Interest Ratio / Days to Cover
Amgen has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Amgen has recently decreased by 2.21%, indicating that investor sentiment is improving.

4.2

Dividend Strength

Dividend Yield
Amgen pays a meaningful dividend of 2.93%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Amgen has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Amgen is 72.06%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Amgen will have a dividend payout ratio of 42.82% next year. This indicates that Amgen will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amgen has received a 53.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Denosumab", "Etanercept", "Darbepoetin alfa", and "Apremilast" products. See details.
Environmental Sustainability
The Environmental Impact score for Amgen is -2.42.

2.9

News and Social Media Coverage

News Sentiment
Amgen has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 86 news articles for Amgen this week, compared to 19 articles on an average week.
Search Interest
95 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 34% compared to the previous 30 days.
MarketBeat Follows
50 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $572,271.00 in company stock.
Percentage Held by Insiders
Only 0.46% of the stock of Amgen is held by insiders.
Percentage Held by Institutions
74.44% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Amgen are expected to grow by 7.57% in the coming year, from $19.54 to $21.02 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amgen is 23.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amgen is 23.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.58.
Price to Earnings Growth Ratio
Amgen has a PEG Ratio of 2.74. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amgen has a P/B Ratio of 24.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amgen Stock (NASDAQ:AMGN)

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMGN Stock News Headlines

February 8, 2024 | marketbeat.com

Are these frigid Dow stocks in for a longer winter? (AMGN)

These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages.

January 31, 2024 | marketbeat.com

IBM, Verizon, Merck stocks lead Dow to new highs (AMGN)

The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance

February 12, 2024 | Stansberry Research (Ad)

HUGE BUY ALERT: Move Fast, Musk…

Since 2018, Eric Wade's investment recommendations have averaged 115%. But one investment he just discovered in Phoenix could blow them all away. It involves Elon Musk, Bill Gates, 32 government mandates, and an AI breakthrough... Not to mention a technology that could help you earn $30,000 a year outside the stock market.

January 25, 2024 | marketbeat.com

5 top healthcare stocks for earnings growth in 2024 (AMGN)

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

January 19, 2024 | marketbeat.com

20 best healthcare dividend stocks to invest in (AMGN)

Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.

January 18, 2024 | marketbeat.com

Dogs of the Dow 2024: Cheap Dividends, But Are They Values?

February 11, 2024 | americanbankingnews.com

Amgen (NASDAQ:AMGN) Given New $278.00 Price Target at Morgan Stanley

February 11, 2024 | americanbankingnews.com

Morgan Stanley Lowers Amgen (NASDAQ:AMGN) Price Target to $278.00

February 12, 2024 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

February 11, 2024 | americanbankingnews.com

Amgen Inc. to Post FY2024 Earnings of $19.54 Per Share, Leerink Partnrs Forecasts (NASDAQ:AMGN)

February 10, 2024 | finance.yahoo.com

Here's Why We're Wary Of Buying Amgen's (NASDAQ:AMGN) For Its Upcoming Dividend

February 10, 2024 | americanbankingnews.com

The Goldman Sachs Group Boosts Amgen (NASDAQ:AMGN) Price Target to $350.00

February 9, 2024 | seekingalpha.com

Amgen Inc. (AMGN) Q4 2023 Earnings Call Transcript

February 9, 2024 | finance.yahoo.com

AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

February 9, 2024 | americanbankingnews.com

Q1 2024 Earnings Forecast for Amgen Inc. (NASDAQ:AMGN) Issued By William Blair

February 9, 2024 | americanbankingnews.com

Royal Bank of Canada Raises Amgen (NASDAQ:AMGN) Price Target to $329.00

February 9, 2024 | americanbankingnews.com

Amgen Inc. Forecasted to Post FY2028 Earnings of $20.92 Per Share (NASDAQ:AMGN)

February 9, 2024 | americanbankingnews.com

Amgen Inc. to Post Q3 2024 Earnings of $4.95 Per Share, William Blair Forecasts (NASDAQ:AMGN)

February 8, 2024 | seekingalpha.com

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

February 8, 2024 | msn.com

Dow drops nearly 100 points on losses for Amgen, Verizon stocks

February 8, 2024 | finance.yahoo.com

Amgen Full Year 2023 Earnings: EPS Misses Expectations

February 8, 2024 | americanbankingnews.com

Amgen (NASDAQ:AMGN) Downgraded by Leerink Partnrs to "Market Perform"

February 8, 2024 | americanbankingnews.com

Amgen (NASDAQ:AMGN) Downgraded to Market Perform at SVB Leerink

February 8, 2024 | americanbankingnews.com

Amgen (NASDAQ:AMGN) Downgraded to "Buy" at StockNews.com

February 7, 2024 | msn.com

Amgen stock suffers worst day in over 2-1/2 years as analysts debate weight loss prospects

February 7, 2024 | finance.yahoo.com

GLP-1s: 'We're investing behind this in a big way,' says Amgen CFO

February 7, 2024 | finance.yahoo.com

Amgen's Weight-Loss Results Are 'A Bit Underwhelming,' Says Lilly Executive

See More Headlines

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/8 Dividend: 11/16/2023
Dividend Payable: 12/08/2023
Last Earnings: 2/06/2024
Today: 2/12/2024
Ex-Dividend for 3/7 Dividend: 2/15/2024
Dividend Payable: 3/07/2024
Next Earnings (Estimated): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Drug Manufacturers - General
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:AMGN
CUSIP: 03116210
CIK: 318154
Web: www.amgen.com
Phone: (805) 447-1000
Fax: 805-447-1010
Employees: 25,200
Year Founded: 1980

Price Target and Rating

Average Stock Price Target: $295.30
High Stock Price Target: $350.00
Low Stock Price Target: $200.00
Potential Upside/Downside: +1.4%
Consensus Rating: Hold
Rating Score (0-4): 2.47
Research Coverage: 19 Analysts

Profitability

EPS (Most Recent Fiscal Year): $12.49
Trailing P/E Ratio: 23.31
Forward P/E Ratio: 14.90
P/E Growth: 2.74
Net Income: $6.55 billion
Net Margins: 23.83%
Pretax Margin: 27.86%
Return on Equity: 154.27%
Return on Assets: 10.95%

Debt

Debt-to-Equity Ratio: 10.14
Current Ratio: 1.65
Quick Ratio: 2.56

Sales & Book Value

Annual Sales: $28.19 billion
Price / Sales: 5.53
Cash Flow: $15.83 per share
Price / Cash Flow: 18.39
Book Value: $11.65 per share
Price / Book: 24.99

Miscellaneous

Outstanding Shares: 535,178,000
Free Float: 532,716,000
Market Cap: $155.80 billion
Optionable: Optionable
Beta: 0.62

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Robert A. Bradway (Age 61)
Chairman, CEO & President
Comp: $5.49M
Mr. Peter H. Griffith (Age 65)
Executive VP & CFO
Comp: $2.57M
Mr. Esteban Santos (Age 56)
Executive Vice President of Operations
Comp: $2.52M
Dr. David M. Reese M.D. (Age 61)
Executive VP & Chief Technology Officer
Comp: $2.83M
Mr. Murdo Gordon (Age 57)
Executive VP of Global Commercial Operations
Comp: $2.72M
Mr. Matthew C. Busch (Age 50)
Chief Accounting Officer & VP of Finance
Mr. Mike Zahigian
Senior VP & Chief Information Officer
Dr. James E. Bradner M.D. (Age 52)
Executive VP of Research and Development & Chief Scientific Officer
Mr. Arvind Sood
Vice President of Investor Relations
Mr. Jonathan P. Graham (Age 63)
Executive VP, General Counsel & Secretary
Comp: $2.44M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amgen stock right now?: 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.
What is Amgen's stock price target for 2024?: 19 Wall Street analysts have issued 1 year price objectives for Amgen's shares. Their AMGN share price targets range from $200.00 to $350.00. On average, they expect the company's share price to reach $295.30 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.
How have AMGN shares performed in 2024?: Amgen's stock was trading at $288.02 at the start of the year. Since then, AMGN stock has increased by 1.1% and is now trading at $291.12.
View the best growth stocks for 2024 here.
When is Amgen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our AMGN earnings forecast.
How were Amgen's earnings last quarter?: Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, February, 6th. The medical research company reported $4.71 EPS for the quarter, beating the consensus estimate of $4.66 by $0.05. The medical research company had revenue of $8.20 billion for the quarter, compared to analysts' expectations of $8.13 billion. Amgen had a net margin of 23.83% and a trailing twelve-month return on equity of 154.27%. Amgen's revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm posted $4.09 earnings per share.
Read the conference call transcript.
How often does Amgen pay dividends? What is the dividend yield for Amgen?: Amgen announced a quarterly dividend on Tuesday, December 12th. Stockholders of record on Friday, February 16th will be given a dividend of $2.25 per share on Thursday, March 7th. This represents a $9.00 annualized dividend and a dividend yield of 3.09%. The ex-dividend date is Thursday, February 15th. This is an increase from the stock's previous quarterly dividend of $2.13.
Read our dividend analysis for AMGN.
Is Amgen a good dividend stock?: Amgen (NASDAQ:AMGN) pays an annual dividend of $9.00 per share and currently has a dividend yield of 2.93%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 72.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.82% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.
What ETFs hold Amgen's stock?: ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), FT Vest DJIA Dogs 10 Target Income ETF (DOGG) and Invesco Dow Jones Industrial Average Dividend ETF (DJD).

What guidance has Amgen issued on next quarter's earnings?: Amgen updated its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of 18.900-20.300 for the period, compared to the consensus estimate of 20.000. The company issued revenue guidance of $32.4 billion-$33.8 billion, compared to the consensus revenue estimate of $32.7 billion.
What is Robert A. Bradway's approval rating as Amgen's CEO?: 1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.
What other stocks do shareholders of Amgen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).
Who are Amgen's major shareholders?: Amgen's stock is owned by many different retail and institutional investors. Top institutional investors include Primecap Management Co. CA (2.73%), Charles Schwab Investment Management Inc. (1.94%), Norges Bank (1.01%), California Public Employees Retirement System (0.51%), Dimensional Fund Advisors LP (0.46%) and LSV Asset Management (0.34%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends.
How do I buy shares of Amgen?: Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Amgen have any subsidiaries?: The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More

This page (NASDAQ:AMGN) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amgen (AMGN) Stock Price, News & Analysis

Amgen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Amgen Stock (NASDAQ:AMGN)

AMGN Stock Price History

AMGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

AMGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™